Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Pamela Esposito
23 Dec 2020
Chief Business Officer
Exercised, kept
50,704
$1.75
$88.73K
Pamela Esposito
11 Dec 2020
Chief Business Officer
Exercised, kept
12,590
$3.30
$41.55K
Showing 250 of 279 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 282
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 25
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 32
Sales at will 226
Transactions with no price 0
Shares from compensation/vesting 31,126,773
Sales filed before the plan box existed 186
History held since 25 Jul 2018